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Objectives: Upon completion of this article, the reader will be
able to identify (1) considerations that determine choice of
anticoagulant; (2) advantages and pitfalls of the direct acting
oral anticoagulants; and (3) anticoagulation management in
special populations, such as those with obesity, cancer, and
renal dysfunction.
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Deep vein thrombosis (DVT) and pulmonary embolism
(PE) are considered to be aspects of the samedisease from the
standpoint of etiology and approach to management, and
together they are commonly referred to as venous thrombo-
embolism (VTE). The estimated annual incidence of VTE is
300,000 to 600,000 cases in the United States alone.1 Several
new anticoagulant drugs have been approved for the treat-
ment of VTE in recent years. These are all oral agents that
specifically target either coagulation factors IIa or Xa, and are
referred to as direct acting oral anticoagulants (DOACs),
sometimes also termed new oral anticoagulants (NOACs)
or target-specific oral anticoagulants (TSOACs).2 A recent
meta-analysis of clinical trials comparing the DOACs to
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Abstract Several new oral anticoagulants have recently been approved for the treatment of
venous thromboembolism (VTE). In this review, we discuss the currently approved
drugs and the factors that influence the choice of anticoagulant in a given patient. Once
anticoagulation is initiated, periodic monitoring of adequacy of anticoagulation may be
necessary depending on the choice of anticoagulant and patient-related factors, such as
renal function. Situations that may warrant need for monitoring and the tests available
for this purpose are discussed. We review reversal of anticoagulation in urgent/
emergent situations as well as perioperative anticoagulation interruption in the elective
setting. The data on use of direct oral anticoagulants in patients with compromised
renal function, obesity and bariatric surgery, and in the treatment of cancer-associated
thrombosis are discussed. The review aims to provide the clinician with the essential
information to allow effective and safe use of anticoagulants for the treatment of VTE.
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vitamin K antagonists (VKAs; e.g., warfarin) found that the
DOACs were as efficacious as VKAs, but had a more favorable
bleeding risk profile, that is, less fatal, intracranial, major and
clinically relevant nonmajor bleeding in patientswith VTE.3,4
This has resulted in the DOACs being recommended over
VKAs for the management of non–cancer-associated VTE in
recent antithrombotic treatment guidelines.5,6 This review
will focus on the approach to initiation of anticoagulation for
the treatment of acute VTE, including laboratory consider-
ations and factors that determine suitability for use of the
newer agents. We will also discuss strategies for reversal of
anticoagulation in case of major bleeding and the use of
DOACs in certain subgroups of patients, such as those with
cancer, obesity, and renal impairment where there are
limited data to guide their use.
Initiation of Anticoagulation
Currently approved agents for the treatment of VTE are
summarized in ►Table 1. In general, DOACs are recom-
mended over VKA in patients with VTE,5,6 but several factors
should be considered in determining the appropriate antico-
agulant drug for an individual patient. These can be broadly
subdivided into patient-specific factors, comorbidities, and
disease-specific factors. The patient’s preference, conve-
nience of anticoagulant drug and lifestyle/dietary habits
also factor into the decision on choice of anticoagulant. These
are summarized in ►Table 2.
A.DOACs: Prior to initiation of DOAC therapy, the following
baseline laboratory tests should be obtained:
• Complete blood cell count (CBC) to ensure an adequate
platelet count
• Serum creatinine with calculation of glomerular filtra-
tion rate (GFR)
• Assessment of liver function. The authors consider an
aspartate transaminase (AST), alanine transaminase
(ALT), and total bilirubin to be appropriate tests, but it
is not clear whether these tests are really needed in
patients with no known liver disease.
Once DOAC therapy is initiated, periodic measurement of
laboratory tests is not needed if the baseline tests are normal.
However, in the patient with comorbid diseases or the
elderly, periodic serum creatinine measurements are appro-
priate. In any patient on long-term anticoagulation, an annual
CBC may be appropriate to screen for the development of
anemia from overt or occult bleeding.
Table 1 Approved anticoagulant drugs for treatment of VTE
Drug Treatment dose Dose adjustment for renal function
Unfractionated heparin Continuous IV:
80 U/kg bolus followed by infusion at
18 U/kg/h; infusion rate adjusted to
maintain aPTT 1.5–2 baseline
SQ: 333 U/kg followed by 250 U/kg BID
None recommended
Enoxaparin
(Lovenox)
1 mg/kg SQ BID (or)
1.5 mg/kg SQ once daily
For CrCl < 30 mL/min
Dalteparin (Fragmin) Month 1: 200 IU/kg SQ once daily
Month 2 onward: 150 IU/kg SQ once daily
Total daily dose not to exceed 18,000 IU
For CrCl < 30 mL/min, adjust dose to
maintain anti-Xa level 0.5–1.5 IU/mL
Tinzaparin (Innohep) 175 IU/kg SQ once daily Use with caution for CrCl < 30 mL/min;
avoid in patients 90 years or older with
CrCl < 60 mL/min
Fondaparinux (Arixtra) Weight <50 kg: 5 mg SQ once daily
Weight 50–100 kg: 7.5 mg SQ once daily
Weight >100 kg: 10 mg SQ once daily
Use with caution for CrCl 30–50 mL/min,
avoid if CrCl <30 mL/min
Vitamin K antagonists (Warfarin)
(Coumadin, Jantoven)
Dose titration to therapeutic INR between 2
and 3
None recommended
Dabigatran (Pradaxa) 150 mg PO BID after 5–10 days of paren-
teral anticoagulation
Avoid if CrCl <30 mL/min
Rivaroxaban (Xarelto) First 3 wk: 15 mg PO BID
After 3 wk: 20 mg PO once daily
Avoid if CrCl <30 mL/min
Apixaban (Eliquis) First week: 10 mg PO BID
After first week: 5 mg PO BID
After “at least 6 mo”: 2.5 mg PO BID
None recommended
Edoxaban (Savaysa) 60 mg PO once daily after 5–10 days of
parenteral anticoagulation
For CrCl <15–50 mL/min; avoid if CrCl
<15 mL/min
Abbreviations: SQ: subcutaneously; PO: by mouth; BID: twice daily; CrCl: creatinine clearance.
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B. VKAs: Prior to the initiation of low-molecular-weight
heparin (LMWH)/VKA treatment, a CBC, serum creatinine,
and prothrombin time (PT) should be obtained.
Among the DOACs, factors such as renal function, comor-
bidities, and patient preference help determine which agent
is best suited for an individual patient. Some real-life scenari-
os to illustrate this are listed below:
• In general, a DOAC that can be initiated without need for
initial LMWHbridge (i.e., rivaroxaban and apixaban) and is
dosed once daily (i.e., Rivaroxaban) is preferred by patients
and providers.
• In the setting of renal insufficiency, a DOAC that is least
dependent on renal function for elimination (apixaban—only
25% cleared by kidneys) or an agent that is not dependent
on renal function at all (VKAs) would be preferred.
• Inpatients at high risk for bleeding, aDOACwith an approved,
specific reversal agent (i.e., dabigatran) or VKAs would be
preferred over an anticoagulant that does not have one.
• In a patient with impaired intestinal absorption, that is,
one who had small bowel resection or bariatric surgery, a
drug whose anticoagulant effect can be monitored (VKAs)
is preferred over one that cannot be easilymonitored (i.e., a
DOAC).
• Cost of the anticoagulant drug and, in the case of VKAs, the
cost associated with monitoring need to be considered. A
patient’s copay for the drug cost needs to be assessed. All
companies making DOACs have patient support programs
through which many patients can get a DOAC for a low
copay.
• In a patient with concern for nonadherence to therapy, an
anticoagulant that can be monitored is preferred (VKA),
but even then significant management problems remain.
Monitoring of Anticoagulation
The need for ongoing monitoring of anticoagulation is deter-
mined primarily based on the type of anticoagulant used.
Traditional anticoagulants such as unfractionated heparin
(UFH) and VKAs require scheduledmonitoring as dose adjust-
ments are likely to be required periodically.
LMWHs: Routine monitoring for adequacy of anticoagula-
tion is not required for LMWHs. The PT and activated partial
thromboplastin time (aPTT) are not sensitive for monitoring
LMWHs. If necessary, the level of anticoagulation with
LMWHs can be evaluated by measurement of the anti-Xa
activity. This test is available at most tertiary centers and can
also be ordered as a “send-out” test to a referral test center if
not offered at the local laboratory. It is important to notify the
laboratory which specific LMWH the patient is on, as this
influences the calibrator which the laboratory uses with the
anti-Xa assay. The blood sample should be obtained 3 to 4
hours after the SQ injection of LMWH, that is, the time when
the peak level is reached. The target therapeutic range varies
based on once or twice daily dosing: for twice daily dosing, it
is 0.6 to 1.0 U/mL; for once daily dosing, it is 1.0 to 2.0 U/mL.
DOACs: Similar to LMWHs, routine monitoring of antico-
agulant activity is not required or recommended for the
DOACs, that is, the direct thrombin inhibitor (dabigatran)
and the Xa inhibitors (apixaban, edoxaban, and rivaroxa-
ban). These agents do not prolong the PT or aPTT reliably
enough that these tests would be useful for monitoring.
Table 2 Factors influencing choice of anticoagulant drug
Comments
Patient-related factors
• Patient preference
• Weight
• Poor adherence to therapy
Preferred may be a once daily drug or agent with an approved antidote; one without dietary
restrictions; a drug that does not require routine monitoring; and one with fewer drug–drug
interactions
Insufficient data exit for the use of DOACs in patients <50 kg and >120 kg (or a body mass
index >40 kg/m2); thus, VKA may be a better choice.
An easily monitored agent may be a better choice
Patient comorbidities
• Renal insufficiency
• Liver disease
• H/o GI bleeding
• H/o gastric
bypass/resection or small
bowel/colon resection
Agents with elimination that is not dependent or minimally dependent on renal or liver
function would be preferred
VKAs or apixaban would be preferred based on data from the atrial fibrillation trials
DOACS are not good options because of unpredictability of absorption; VKA strongly
preferred
Disease-related factors
• Cancer-associated VTE
• Splanchnic vein thromboses
• Antiphospholipid syndrome
LMWHs preferred.
DOACs or VKAs reasonable; limited data on the use of both
DOACs or VKAs reasonable; data on DOAC use limited to case series; VKAs have a high failure
rate
Abbreviations: DOACs, direct oral anticoagulants; LMWH, low-molecular-weight heparin; VTE, venous thromboembolism.
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More specialized coagulation tests to assess the DOAC’s
anticoagulant activity have been evaluated and correlate in a
linear fashion with concentrations of the DOACs. Mass spec-
trometry drug testing for the DOACs is also offered by some
commercial laboratories and provide reliable drug levels. These
tests can, therefore, be used for DOAC monitoring purposes.
However, they are as yet not widely available.
Dabigatran: The thrombin time (TT) is highly sensitive to
dabigatranandis,thus,asensitivescreenforthepresenceofany
dabigatranconcentrationintheplasma.However,attherapeutic
drug levels, the TT is invariably unmeasurably prolonged and,
therefore,notausefultesttoquantifytherapeuticorsuprather-
apeuticlevels.Thedilutethrombintime(dTT)andtheEcarintime—
either as a clottingor as a chromogenic assay—aregood tests to
quantifysubtherapeutic,therapeutic,andsupratherapeuticlev-
els.Similarly,massspectrometrydrugleveltestingcanbeusedfor
thispurpose.
Apixaban, edoxaban, and rivaroxaban: The anticoagulant
effect of these agents can be reliably measured using anti-Xa
activity assays if the assay is calibrated with drug-specific
standards. They can also be tested via mass spectrometry.
However, these tests are also not easily available at this point.
While they can be obtained through commercial referral
laboratories, the turnaround time is often 3 to 7 days, and
the results may be reported without therapeutic ranges pro-
vided. The latter is because there are no recommended “ther-
apeutic” levels for these drugs.Whendrug levels aremeasured,
it is generally to evaluatewhether the result iswithin expected
ranges for peak or trough levels for the given drug.7 However,
therapeutic ranges arewide and the correlation between levels
and efficacy and safety has only been established for some, but
not all of the DOACs.8,9 Dose adjustments of DOACs based on
measured drug levels should not be undertaken, as this
practice lacks clinical evaluation. Situations when a clinician
may consider testing are listed in ►Table 3.
Reversal of Anticoagulation
Immediate reversal of anticoagulation may be needed in the
setting of major bleeding or need for urgent/emergent sur-
gery. Only urgent reversal will be discussed in this section.
The approach to perioperative interruption of anticoagula-
tion in the setting of elective procedures is discussed sepa-
rately. Several anticoagulants have approved drug-specific
antidotes. These are summarized in ►Table 4.
At the University of North Carolina at Chapel Hill, we have
developed institutional guidelines for urgent reversal for all
anticoagulant drugs. This resource for healthcare providers is
available at https://www.med.unc.edu/emergmed/files/
emergent-anticoagulation-reversal-guideline-unc-health-
care.
Dabigatran reversal: A target-specific antidote has been
developed for reversal of dabigatran. Idarucizumab (Prax-
bind) is a monoclonal antibody fragment that binds to
dabigatran with an affinity that is 350-fold greater than the
affinity of dabigatran for thrombin. Idarucizumab, therefore,
binds both free and thrombin-bound dabigatran effectively.10
The reversal dose is 5 g administered as an intravenous bolus.
The reversal effect after one bolus dose lasts for at least 24
hours, so that there is no need for continued or repeated
antidote dosing. A prospective, multicenter, cohort study to
evaluate the efficacy and safety of idarucizumab for the
reversal of anticoagulation in patients with life-threatening
bleeding or need for urgent/emergent surgical procedures is
ongoing (RE-VERSE AD trial). The target for enrollment is 300
patients and data on the initial 90 patients enrolled in this
trial were recently published.11 Idarucizumab administration
resulted in rapid and complete reversal of anticoagulation in
88 to 98% of patients who had elevated clotting times prior to
reversal.11 Furthermore, of the patients in whom anticoagu-
lation was reversed for surgery, 92% underwent surgery
successfully and without problems achieving hemostasis.
There were no major bleeding complications. Idarucizumab
was approved by the U.S. Food and Drug Administration (FDA)
in October 2015 and by the European Medicines Agency in
November 2015.
Anti-Xa drug reversal: The subset of anticoagulant drugs
without approved drug-specific antidotes is the oral anti-Xa
agents. Potential approaches to restore hemostatic potential
with the use of these agents include administration of a
single dose of the following: four-factor prothrombin
complex concentrate (PCC; KCentra; 50 U/kg intravenously)
or activated prothrombin complex concentrate (aPCC; FEIBA;
80 U/kg). It is our preference to use the four-factor PCC in
this setting, given that it has less of a risk of thrombosis than
aPCC.
Andexanet alfa is a target-specific antidote with efficacy
against all anticoagulants that target factor Xa. It is not FDA
approved as of September 2016. Andexanet alfa is a recombi-
nant modified factor Xa protein that retains capability to bind
anti-Xa drugs but is not biologically functional (no catalytic or
membrane-binding activity). The interim report on the first
67 patients treated in the ongoing multicenter, prospective,
open-label clinical trial (ANNEXA-4) on the use of Andexanet
for reversal of anticoagulation associated with four anti-Xa
agents (rivaroxaban, apixaban, edoxaban, and enoxaparin)
was recently published.12 Andexanet was administered as an
intravenous bolus followed by a 2-hour infusion. Andexanet
was effective in decreasing anti-Xa activity by more than 80%
by the end of the infusion and excellent or good hemostatic
activity was achieved in 79% of the patients. This study is
ongoing and the targeted enrollment is 162 and 230 patients
for efficacy and safety outcomes, respectively. The FDAdid not
Table 3 Situations where monitoring of DOACs should be
considered
• Obesity (BMI >40 kg/m2; weight >120 kg)
• Underweight (<50 kg)
• Concern over interfering medications
• Fragile, elderly patients
• Borderline renal function
• Recurrent thrombosis on DOAC therapy
• Major bleeding on DOAC therapy
• Assessing persistent DOAC plasma levels prior to surgery
• Assessing patient adherence to anticoagulant therapy
Abbreviations: BMI, body mass index; DOACs, direct oral anticoagulants.
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approve Andexanet in a decision on August 18, 2016, and has
apparently requested more information from the manufac-
turer, specifically information related tomanufacturing of the
drug, and additional data to support inclusion of edoxaban
and enoxaparin in the label. The FDA also intends to finalize
its reviewof themanufacturer’s proposals for post-marketing
data collection on the performance of Andexanet. A new FDA
decision is expected sometime in 2017.
VKA reversal: The approach to reversal of VKA anticoagula-
tion is to restore sufficient activity of the vitamin K–dependent
coagulation factors (factors II, VII, IX, X, protein C, protein S, and
protein Z). Traditionally, this was achieved by concomitantly
administered vitamin K (intravenously or orally) and infusing
fresh frozen plasma (FFP). This approach had certain drawbacks:
(1) multiple units of FFP are necessary in patients with a supra-
therapeutic PT/INR (international normalized ratio) with the
risk of volume overload in patients with compromised
cardiac function; (2) FFP contains a lot more than just the
vitamin K–dependent clotting factors and patients are obligated
to be exposed to them; (3) ABO typing is necessary for FFP and
the units also need to be thawed/prepared prior to administra-
tion and there tends to be longer than a 60-minute delay from
the time the product was requested to the time of infusion.
Finally, it takes 12 to 24 hours for the vitamin K to impact
hemostatic ability in any meaningful way.
PCCs are plasma-derived, pooled, clotting factor concen-
trates that contain only the vitamin K–dependent factors
without extraneous proteins, so that only the clotting factors
affected by VKAs are replaced. Volume overload is seldom an
issue with these agents. PCCs are available as “four-factor
concentrates” and “three-factor concentrates.” The difference
is primarily that the four-factor concentrates (e.g., KCentra)
have factors II, VII, IX, and X, while the three-factor concen-
trates (Bebulin, Profilnine) do not contain significant amounts
of factor VII. A prospective clinical trial evaluating four-factor
PCC versus FFP showed that four-factor PCC was noninferior
to FFP for hemostatic efficacy.13 Further, four-factor PCC
resulted in rapid INR reduction and increased plasma levels
of the vitamin K–dependent coagulation factors (>60% activ-
ity) compared with FFP—30 minutes for four-factor PCC
versus approximately 6 hours for FFP to achieve comparable
levels.13 For these reasons, and given the significantly smaller
volume and ability to administer the drug quickly in the
urgent/emergent setting (no thawing or ABO typing needed),
four-factor PCCs are the preferred agents for urgent reversal of
VKA anticoagulation. KCentra was approved by FDA in 2013
for reversal of VKA anticoagulation in the setting of major
bleeding or urgent reversal for other reasons.13,14 In cases
where PCCs are not available, patients should receive FFP and
vitamin K for reversal.
Table 4 Urgent reversal of anticoagulation with specific antidotes
Anticoagulant drug Reversal agent (dose) Comments
UFH Protamine
(1 mg/100 U of heparin)
Consider only amount of heparin administered in
the 3 h prior to protamine for dose calculation.
Risk for allergic/hypersensitivity reactions in
patients with fish allergy or previous protamine
exposure
Cap protamine at 50 mg/dose.
Reversal effect in 5–10 min, monitor aPTT
Repeat doses may be necessary
LMWH Protamine
(1 mg/mg of LMWH if anticoagulant given <8 h
prior to protamine)
(0.5mg/mg of LMWH if anticoagulant given 8–12 h
prior to protamine)
Protamine does not completely reverse LMWH
(60% of LMWH anti-Xa activity).
Risk for allergic/hypersensitivity reactions in
patients with fish allergy or previous protamine
exposure.
Repeat dose at 0.5 mg/mg LMWH if bleeding
persists or elevated anti-Xa activity after 4 h
VKAs PCC
(KCentra; 25–50 U/kg infusion depending on INR)
Also administer vitamin K 5–10 mg IV/PO.
PT/INR check 10–30 min after PCC dose to assess
efficacy
Repeat PT/INR Q6 h  4 given short half-life of
PCCs
Dabigatran Idarucizumab
(Praxbind; 5 g IV)
Monoclonal antibody fragment that binds dabiga-
tran with high affinity
In the setting of acute renal failure, hemodialysis
may be considered to facilitate drug elimination
Anti-Xa agents Andexanet
(AndexXa in the United States, IndexXa in Europe)
Clinical trial ongoing; not FDA approved as of
September 8, 2016
Abbreviations: aPTT, activated partial thromboplastin time; INR, international normalized ratio; LMWH, low-molecular-weight heparin; PCC,
prothrombin complex concentrate; PT, prothrombin time; UFH, unfractionated heparin; VKA, vitamin K antagonist; VTE, venous thromboembolism.
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Perioperative Management of
Anticoagulation
Brief interruption of anticoagulation for elective procedures
or surgeries is a relatively common occurrence.Wewill divide
this section into pre- and postoperative periods for ease of
discussion.Wewill discuss patientswith intact renal function
in this section, whereas management in patients with renal
insufficiency is discussed later.
Preoperative period: The decision on how soon before the
procedure anticoagulation must be withheld depends on the
half-life of the anticoagulant drug and the risk of bleeding
associated with the procedure (low, moderate, or high as
outlined in the Society for Interventional Radiology (SVIR)
consensus guidelines15).
In hospitalized patients on therapeutic anticoagulation
with an UFH infusion, the infusion should be held 4 hours
prior to the procedure, given the short half-life of UFH. In the
case of therapeutic LMWH dosing, the time of drug discon-
tinuation depends on whether LMWH is being given once or
twice daily. In general, the last LMWH dose should have been
given 24 hours before the procedure. This translates to
holding the dose of twice daily enoxaparin the evening (12
hours) and the morning before the procedure or the dose of
once daily dalteparin, enoxaparin, or fondaparinux themorn-
ing (24 hours) before the planned procedure.
In patients on VKAs with a therapeutic INR, anticoagula-
tion is held 5 days prior to the procedure to allow the PT/INR
to drift down to normal. In individuals who had their episode
of acute VTE within the last 3 months, bridging with LMWH
once the INR has drifted below 2 and until the morning 1 day
(i.e., 24 hours) before the procedure is recommended, given
the increased risk for VTE recurrence in such individuals. On
the other hand, in patients with a remote history of VTE
(> 3 months before procedure), pre-procedure LMWH bridg-
ing following discontinuation of VKA is not needed.
Until recently, the vast majority of patients requiring
interruption of anticoagulation were on VKAs. Since the
advent of DOACs, there is some degree of uncertainty on
how to safely interrupt anticoagulation in patients on
DOACs. An ongoing clinical study is investigating the effec-
tiveness and safety of a proposed DOAC interruption
scheme (PAUSE study, ClinicalTrials.gov Identifier:
NCT02228798). Until we learn the best management
from the results of that study, DOACs should be withheld
24 to 36 hours prior to procedure if the bleeding risk is low
or moderate, and 2 to 4 days prior to procedure if the
bleeding risk associated with the procedure is high (e.g.,
transjugular intrahepatic portosystemic shunt (TIPS), renal
biopsy).16,17 However, renal function is important to con-
sider, as renal impairment leads to prolonged DOAC half-
life and the need to discontinue the DOAC even earlier
before the procedure. There is no need for LMWH bridging
when the DOACs are held pre-procedure.
Postoperative period: Therapeutic anticoagulation is
generally resumed 8 to 24 hours postprocedure, but the
timing depends on the bleeding risk associated with the
procedure. In the case of hospitalized patients on UFH, the
heparin infusion should be resumed without a bolus and at
the pre-procedure UFH infusion rate to decrease risk for
bleeding. LMWH can similarly be resumed at the preproce-
dure dose. Patients on VKAs will require postprocedure
bridging with LMWH for at least 5 days and until the INR is
in the therapeutic range, which typically takes 5 days.
Patients on DOACs can resume the drug at preprocedure
dose and no LMWH bridging is needed. The timing of
resumption of anticoagulation and/or the dose of the antico-
agulant may need to be modified based on patient- and
procedure-specific factors. In situations where oral intake is
delayed (e.g., abdominal surgery), patients can be managed
with LMWH and transitioned to the DOAC when clinically
appropriate.
DOAC Use in Special Circumstances
Renal Insufficiency/Failure
There are considerable differences between the DOACs in
terms of dependence on renal function for drug elimination.
Dabigatran ismost dependent on renal function, as 80% of the
drug is cleared by the kidneys. Edoxaban’s and rivaroxaban’s
clearance is approximately 35% dependent on the kidney.
Apixaban has themost favorable profile in this setting, as only
approximately 25% of the drug’s clearance is dependent on
renal function.
The dosing guidelines recommend avoiding use of dabiga-
tran and rivaroxaban in patients with creatinine clearance
<30 mL/min (►Table 1). Similarly, dosing guidelines recom-
mend avoiding use of edoxaban in patients with creatinine
clearance <15 mL/min and dose reduction for creatinine
clearance between 15 and 50 mL/min (►Table 1). The pre-
scribing guidelines for apixaban do not recommend any dose
adjustment for renal insufficiency/failure. However, patients
with creatinine clearance <15 mL/min were not studied in
the efficacy and safety trials. Apixaban has been evaluated in
patients with renal failure undergoing hemodialysis or with
various degrees of renal impairment, albeit in small numbers
and after a single dose of drug.18,19 These studies concluded
that renal failure has limited impact on apixaban levels in
patients with renal impairment, renal failure, or on regular
hemodialysis.
We recommend VKAs as the first choice in patients with
renal insufficiency/failure. It is our practice and recommen-
dation that dabigatran and rivaroxaban be avoided in patients
with renal insufficiency and creatinine clearance <40 mL/
min. Apixaban could be considered in patients with renal
insufficiency as a second-line option to VKAs, but we do not
recommend its use in patients with renal failure until more
evidence is available to support the safety of this practice.
Cancer-Associated Thrombosis
Data on the use of DOACs in patients with cancer are limited.
There are retrospective case series that suggest that these
agents are effective in patients with cancer-associated throm-
bosis. A meta-analysis of cancer patients who participated in
the DOAC clinical trials found DOACs were as effective and
safe as VKAs.20 Three large prospective clinical trials
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comparing LMWHs to DOACs for the treatment of cancer-
associated VTE are ongoing.
Current guidelines recommend LMWHs as the preferred
agents for the treatment of cancer-associated VTE.5,21 In
patients in whom LMWHs are not an option (cost, patient
preference, etc.) DOACs can be considered. DOACs are more
convenient than warfarin in cancer patients, as their quick
onset of action and their shorter half-life allow better antico-
agulant management at times of thrombocytopenia compared
with VKAs. However, DOACs and VKAs also share several
disadvantages when it comes to cancer patients: a patient’s
poor oral intake and gastrointestinal problems (nausea and
vomiting) and the DOACs’ interactions with chemotherapeutic
agents may limit their use/efficacy in this population.
Obesity
The phase III trials of the DOACs included patients who were
obese (defined as a body mass index [BMI] >30 kg/m2), but
the numbers of patients with extreme body weights
(> 120 kg or BMI > 40 kg/m2) were limited. There is uncer-
tainty regarding the efficacy of DOACs in extremely obese
patients, as the limited pharmacokinetic/pharmacodynamic
data available raise concern over decreased peak concentra-
tions and half-lives in patients with BMI >40 kg/m2. The use
of DOACs in obese patients was specifically addressed in a
recent guidance document from the International Society on
Thrombosis and Hemostasis (ISTH).22 Our practice regarding
the use of DOACs in obese patients is in keeping with the ISTH
guidance, which recommends the following: (1) avoiding
DOACs in patients with BMI >40 kg/m2 or weight >120 kg
and (2) if DOACs are used in these patients, monitoring drug
levels to ensure the levels are within the expected peak and
trough range for the given drug.
Bariatric Surgery
All orally taken anticoagulants are absorbed in the small
intestine (duodenum, jejunum), some also partially in the
distal stomach. However, limited data on the exact location of
absorption exist for the DOACs. The anatomic changes after
bariatric surgeries (i.e., gastric banding, sleeve gastrectomy,
Roux-en-Y gastric bypass, and biliopancreatic diversion) not
only affect the area available for drug absorption but also the
amount of food intake, gastric and small intestinal transit
time, and gastric and duodenal acidity. Al these factors lead to
an unpredictable absorption of DOACs after bariatric surgery.
Therefore, our practice in patients who have undergone
bariatric surgery and who require anticoagulation is to use
VKAs which can easily bemonitoredwith the INR rather than
to use a DOAC.
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